Healthcare
•1072 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (1072)
%
| Company | Market Cap | Price |
|---|---|---|
|
NXTC directly develops and pursues Antibody-Drug Conjugates (ADCs) as its lead oncology therapies (LNCB74, SIM0505).
|
$15.54M |
$6.65
+5.59%
|
|
Biotech - Oncology reflects a stated biotech arm (Fuse Biotech) with potential oncology-focused therapies or programs.
|
$15.41M |
$0.24
|
|
Company develops neuropsychiatric therapeutics (BXCL501) for agitation, a CNS/psychiatric drug development program.
|
$15.32M |
$2.53
-3.80%
|
|
PolyPid's PLEX is a proprietary drug delivery platform enabling localized, prolonged release of APIs at the surgical site, core to the business.
|
$15.11M |
$3.15
-3.96%
|
|
Core medical device product: swallowable intragastric Allurion Balloon.
|
$14.92M |
$2.00
-6.98%
|
|
Athira's lead program ATH-1105 targets ALS, a CNS neurodegenerative condition, aligning with neuropsychiatric/CNS drug development themes.
|
$14.84M |
$3.80
-3.06%
|
|
AMS directly deploys and operates medical radiation therapy devices (Gamma Knife, LINACs, PBRT) in its Direct Patient Services centers.
|
$14.84M |
$2.30
-4.56%
|
|
TLANDO and pipeline candidates are formulated as oral small‑molecule therapeutics, aligning with the tag.
|
$14.61M |
$2.73
-1.80%
|
|
AYTU's ADHD and pediatric neuropsychiatric portfolio places it in the neuropsychiatric drug development / CNS category.
|
$14.56M |
$2.36
-7.45%
|
|
REMONY remote monitoring and continuous vital-sign data collection align with patient monitoring.
|
$14.34M |
$2.14
+3.38%
|
|
LB-100 is Lixte's lead oncology drug (PP2A inhibitor) and the core product being developed for cancer indications.
|
$14.28M |
$5.32
-3.80%
|
|
The company explicitly markets an Antibody Discovery Platform as a core capability in its AI-driven antibody development approach.
|
$14.19M |
$0.81
-0.30%
|
|
Lead asset solnerstotug is an oncology monoclonal antibody therapy targeting VISTA.
|
$14.19M |
$11.26
-5.06%
|
|
Company is advancing an oncology-focused biotech platform (FHAB) with lead asset SON-1010, making oncology the core direct business line.
|
$13.96M |
$4.41
-6.96%
|
|
Includes regulatory advisory and compliance support services, aligning with Laboratory Testing & Advisory Services as a service category.
|
$13.82M |
$0.60
|
|
The company licenses RNA interference assets (siRNA) and pursues RNAi therapeutics development as part of its pipeline.
|
$13.56M |
$1.44
-4.64%
|
|
Exclusive KRAS gene-related license, aligning with biotech/gene therapy applications.
|
$13.32M |
$0.12
|
|
NVNO's VenoValve is a surgically implanted device used to treat deep venous CVI, aligning with the 'Surgical Equipment' category.
|
$13.01M |
$0.74
-14.74%
|
|
Co-Diagnostics' core product is the Co-Dx PCR platform—a diagnostic instrument for portable, point-of-care PCR testing.
|
$12.92M |
$0.38
+3.59%
|
|
Offers diagnostic-ready sensor solutions (liquid-phase bio-chemical sensors) suitable for medical diagnostics and biomarker detection.
|
$12.75M |
$0.04
+2.94%
|
|
LYMPHIR is an FDA-approved targeted immunotherapy for CTCL (cancer), representing a core oncology biotech product.
|
$12.66M |
$1.23
-6.11%
|
|
Legacy Quarta-Rad product line includes Geiger counters / radiation detectors; mapped to Diagnostic Equipment as a product category.
|
$12.23M |
$0.80
|
|
Longeveron's lead candidate laromestrocel is a mesenchymal stem cell (MSC) based cell therapy.
|
$12.20M |
$0.81
-7.66%
|
|
Directly manufactures autologous stem cell therapy (BRTX-100) for chronic lumbar disc disease, a core cell therapy product line.
|
$12.16M |
$1.62
-5.81%
|
|
Travelan (IMM-124E) and related gut-health antibody products are prophylactic biologics targeting enteric pathogens, aligning with the Vaccines category.
|
$11.80M |
$2.07
-2.36%
|
|
LungFit is described as a drug delivery platform for nitric oxide, i.e., a platform technology for NO delivery.
|
$11.78M |
$2.54
-5.58%
|
|
Biotechnology segment with oncology-focused programs and pipeline support.
|
$11.75M |
$1.29
-4.30%
|
|
Diagnostic Equipment: imaging and analytics equipment used for threat detection and material identification.
|
$11.70M |
$0.62
+8.92%
|
|
Company is actively developing antiviral small-molecule therapeutics across influenza, norovirus/coronavirus, and HCV indications.
|
$11.70M |
$1.15
-7.26%
|
|
IHL-42X and the firm’s other pipeline assets are delivered as oral small-molecule therapeutics (oral drugs).
|
$11.53M |
$0.39
-9.33%
|
|
Core product platform MAR-T cell therapy (multi-antigen T-cell therapy) for cancer.
|
$11.43M |
$1.01
-4.72%
|
|
MDxHealth offers liquid biopsy diagnostic tests (Select mdx, ExoDx) for prostate cancer and urinary tract infections, classifying them under Liquid Biopsy.
|
$11.13M |
$4.08
-7.06%
|
|
Bolt's Boltbody ISAC platform is an antibody discovery/conjugate platform central to its products, qualifying as an 'Antibody Discovery Platform' investment theme.
|
$11.12M |
$5.80
-1.60%
|
|
Directly involved in oncology-focused cellular therapies as a platform for CAR-Macrophages used to treat solid tumors.
|
$10.90M |
$0.24
-6.09%
|
|
Check-Cap directly manufactures diagnostic equipment as part of its C-Scan system (capsule, wearable track, and viewing software) for CRC screening.
|
$10.77M |
$1.84
-8.00%
|
|
OSR Holdings' VAXIMM AG focuses on oral immunotherapies for cancer, aligning with Oncology-focused biotechnology.
|
$10.69M |
$0.55
-9.02%
|
|
PHIO develops innovative oncology therapies leveraging IO and immune modulation in cancer, aligning with Biotech - Oncology.
|
$10.57M |
$2.20
-7.09%
|
|
Gelteq oversees manufacturing of its gel-based delivery systems and relies on CMOs with a dedicated facility, a core contract manufacturing service.
|
$10.55M |
$1.30
-2.99%
|
|
AppYea directly manufactures/markets at-home wearables for sleep monitoring (AppySleep).
|
$10.37M |
$0.02
-13.97%
|
|
Handheld ballast water checker device functions as diagnostic equipment for compliance screening.
|
$10.36M |
$1.34
-1.45%
|
|
Company manufactures medical-grade silicon nitride materials and devices, central to its core medical device business.
|
$10.31M |
$4.11
+7.31%
|
|
MHUA lists medical imaging consumables (e.g., disposable X-ray films) as part of its product portfolio, aligning with Medical Imaging.
|
$10.18M |
$0.39
-6.47%
|
|
LYR-210 is an implantable prosthetic/implant delivering localized corticosteroid therapy, categorizing under Prosthetics & Implants.
|
$10.17M |
$7.67
-1.67%
|
|
Software relates to medical imaging/planning workflows used in radiotherapy, aligning with Medical Imaging software.
|
$10.15M |
$0.70
-1.14%
|
|
PALI-2108 is an orally administered small-molecule therapeutic, fitting the Oral Small Molecule Therapeutics category.
|
$9.59M |
$2.00
-3.38%
|
|
Ekso Bionics manufactures medical devices and biometric sensing technologies (exoskeletons for rehabilitation and mobility).
|
$9.56M |
$4.94
-8.86%
|
|
Direct focus on oncology programs (PDAC) with motixafortide data supporting oncology indications.
|
$9.38M |
$3.91
-5.10%
|
|
Core product line: liquid biopsy diagnostics using RNA in blood (VitaGuard MRD integration).
|
$9.32M |
$5.19
-3.71%
|
|
Recurring revenue from medical device consumables used with their equipment.
|
$9.24M |
$0.80
+5.81%
|
|
KALA's lead product KPI-012 is an ophthalmic therapy (cell-free MSC-S secretome) aimed at treating Persistent Corneal Epithelial Defects, aligning with Ophthalmic Drugs.
|
$9.23M |
$1.43
-7.74%
|
|
The company emphasizes proprietary drug formulations and delivery methods as a core moat, mapping to Drug Delivery Platforms.
|
$9.20M |
$0.70
-6.52%
|
|
Aptorum's pipeline includes oncology-focused therapeutics (e.g., SACT-1) in Phase 1, establishing Biotech - Oncology as a core segment.
|
$9.08M |
$1.66
-30.83%
|
|
Directly develops oncology drugs as a biotech company focused on cancer therapeutics.
|
$8.93M |
$0.20
|
|
Directly focused on oncology therapeutics and cancer targets (miR-10b) within a biotech/oncology pipeline.
|
$8.81M |
$10.56
-1.45%
|
|
ReWalk exoskeletons and related wearable mobility devices are prosthetics/implant-type products directly manufactured and sold by Lifeward.
|
$8.79M |
$0.80
-5.39%
|
|
Ib ezapolstat is an oral small-molecule antibiotic, forming the core product in Acurx's pipeline.
|
$8.78M |
$7.48
+10.49%
|
|
Biomica’s microbiome-based therapeutics for human health (immunology-related therapeutics).
|
$8.76M |
$1.29
-3.01%
|
|
Catamaran System and related sacroiliac/spine implants are orthopedic devices.
|
$8.65M |
$1.14
-4.20%
|
|
CELZ's ImmCelz and AlloStem platforms are core cell-therapy products/technologies the company develops and advances.
|
$8.61M |
$3.33
-4.31%
|
|
EsoGuard is a laboratory test/service delivered to clinicians, qualifying as Laboratory Testing & Advisory Services.
|
$8.61M |
$0.49
-13.83%
|
|
Provides outsourced drug discovery services and CRO-like capabilities (lab work, data analysis).
|
$8.53M |
$14.32
+1.31%
|
|
Development and potential commercialization of diagnostic equipment/software (AI-enabled diagnostics).
|
$8.46M |
$0.00
-20.00%
|
|
GeoVax directly develops and commercializes vaccines using its MVA vector platform (e.g., GEO-MVAMpox/smallpox and GEO-CM04S1 COVID-19).
|
$8.44M |
$0.56
-7.43%
|
|
Adrulipase targets exocrine pancreatic insufficiency (EPI), a rare disease indication, placing Entero Therapeutics in Biotech - Rare Diseases.
|
$8.32M |
$5.24
+11.25%
|
|
The company develops ophthalmic drugs (KIO-301 and KIO-104) for retinal diseases.
|
$8.22M |
$2.70
-4.26%
|
|
Direct focus on oncology therapies and cancer immunotherapy platforms.
|
$8.21M |
$0.35
|
|
Immco lab-based diagnostic testing and advisory services (lab testing, HIV screening, preeclampsia, etc.).
|
$8.05M |
$1.05
-3.67%
|
|
Immunology therapeutics targeting inflammatory conditions (TH023, anti-TNF-α antibody delivery).
|
$7.93M |
$2.98
-7.45%
|
|
Directly focused on oncology biotech development (Biotech - Oncology) with DDR pathway inhibitors.
|
$7.85M |
$1.42
-5.33%
|
|
Medicure’s direct prescription cardiovascular drugs (AGGRASTAT and ZYPITAMAG) place it squarely in the Cardiovascular Drugs category.
|
$7.83M |
$0.75
|
|
SpinDx and breathalyzer devices are diagnostic equipment directly manufactured/sold by Lifeloc Technologies.
|
$7.75M |
$3.16
|
|
Linebacker platform primarily targets oncology indications via electrophilically enhanced polyphenol compounds; aligns with biotech oncology category.
|
$7.69M |
$0.64
+0.47%
|
|
Lead asset is an immunology-focused therapeutic targeting autoimmune diseases (systemic lupus erythematosus and Sjogren's), aligning with Immunology Therapeutics.
|
$7.63M |
$1.40
-11.39%
|
|
The company manufactures a portable drug-screening system (IFPG) consisting of a handheld reader and disposable cartridges, i.e., diagnostic equipment.
|
$7.53M |
$1.09
-3.54%
|
|
The GE Healthcare diagnostic imaging equipment and ultrasound systems sold by VasoHealthcare fall under Diagnostic Equipment.
|
$7.48M |
$0.12
+2.27%
|
|
Company is pivoting to an individualized therapy for Treatment Resistant Depression, a neuropsychiatric drug development focus.
|
$7.48M |
$2.33
-5.67%
|
|
Addex's strategy and assets focus on neuropsychiatric drug development (e.g., schizophrenia via Neurosterix M4 PAM program, Dipraglurant for brain injury), fitting Neuropsychiatric Drug Development.
|
$7.43M |
$9.44
+7.49%
|
|
HIHO operates as an OEM/ODM contract manufacturer providing integrated manufacturing and subassembly services.
|
$7.35M |
$1.67
+1.21%
|
|
CBIO directly develops oncology-focused biologic therapies, aligning with the Biotech - Oncology category.
|
$7.32M |
$11.35
-6.81%
|
|
CDIO directly provides Laboratory Testing & Advisory Services through its in-house lab operations for epigenetic/genetic cardiovascular tests (EpiGen CHD, PrecisionCHD, ACI insights).
|
$7.22M |
$4.15
-7.37%
|
|
Biomerica directly manufactures and markets diagnostic tests (inFoods IBS, hpdetect, Fortel tests) and related point-of-care diagnostics.
|
$7.20M |
$2.83
-4.07%
|
|
NovaBay's continuing operations revolve around manufacturing wound care products for export to China, making Wound Care Devices its direct current product focus.
|
$7.15M |
$1.23
-0.81%
|
|
Cellectar directly develops radiopharmaceuticals and radioconjugates for cancer therapy, including its lead iopofosine I-131 and next-generation radiopharmaceuticals.
|
$7.13M |
$4.64
-3.73%
|
|
SBFM operates a Canadian generic prescription drug business (Nora Pharma) with multiple marketed generic drugs, making generic drugs a core revenue driver.
|
$7.06M |
$1.55
-6.63%
|
|
Core business: BioCardia's lead programs CardiAMP and CardiALLO are autologous/allogeneic cell therapies.
|
$7.04M |
$1.36
+0.37%
|
|
BETRF's pipeline includes BETR-001 and BETR-002, non-hallucinogenic neuroplastogens targeting mental health and anxiety-related disorders.
|
$7.04M |
$0.04
-6.38%
|
|
Core focus on CAR T and cell-based therapies (MB-101, MB-109) and oncolytic virus programs, i.e., cell therapy.
|
$6.92M |
$1.56
-0.95%
|
|
PMCB's core offering is oncology cell-based therapy using the Cell-in-a-Box encapsulation platform (CypCaps) to target cancer, notably LAPC.
|
$6.86M |
$1.00
|
|
Boost Diagnostics and Pala Diagnostics provide diagnostic testing services, fitting Laboratory Testing & Advisory Services.
|
$6.85M |
$0.06
+23.91%
|
|
Gimoti is a nasally administered small-molecule metoclopramide product that Evoke Pharma directly commercializes, representing its core pharmaceutical product line.
|
$6.82M |
$4.57
-0.41%
|
|
The narrative describes ongoing laboratory testing activities and regulatory/advisory services critical to bringing diagnostics to market.
|
$6.79M |
$0.04
|
|
Bionano's core offerings include Optical Genome Mapping hardware (Saphyr/Stratys) and the Ionic Purification System, both of which are diagnostic equipment sold to labs.
|
$6.76M |
$2.01
-1.95%
|
|
The WaveECG device is a diagnostic equipment product used for ECG-based cardiac assessment, which directly aligns with Diagnostic Equipment.
|
$6.75M |
$3.49
-6.43%
|
|
MDX Viewer is an FDA-approved diagnostic device that measures tissue oxygenation, directly aligning with Diagnostic Equipment.
|
$6.67M |
$0.07
|
|
The company markets HOCl-based eye-care products (e.g., Lumacyn/Podiacyn), which fit the ophthalmic drugs category.
|
$6.64M |
$4.04
-6.05%
|
|
Core turnkey OEM/ODM contract manufacturing services enabling clients to outsource product development and manufacturing of biotech-nutraceutical/beauty/medical consumables.
|
$6.62M |
$0.03
|
|
Company's lead asset Annamycin is an oncology therapeutic, making Moleculin a cancer-focused biotech with direct drug development in oncology.
|
$6.52M |
$0.46
-5.78%
|
|
Directly develops and commercializes vaccines, including personalized cancer vaccines (EVX-01) and infectious disease vaccines under development.
|
$6.39M |
$5.90
-9.65%
|
|
IN8bio's core program is gamma-delta T cell therapy (INB-100/INB-200) and related iPSC-derived gamma-delta T cell products, i.e., cell therapy.
|
$6.35M |
$2.10
-7.08%
|
|
Company aims to develop Alzheimer's disease therapeutics (AL001 and ALZN002) and thus fits Alzheimer's Disease Therapeutics.
|
$6.31M |
$2.18
-5.63%
|
Showing page 10 of 11 (1072 total stocks)
Loading industry metrics...
Loading comparison data...
